Produktname:tert-butyl N-(4-fluoro-2-methoxy-5-nitrophenyl)carbamate

IUPAC Name:tert-butyl N-(4-fluoro-2-methoxy-5-nitrophenyl)carbamate

CAS:1802924-13-5
Molekulare Formel:C12H15FN2O5
Reinheit:95%+
Katalognummer:CM350166
Molekulargewicht:286.26

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM350166-100mg in stock Ʃţţ
CM350166-250mg in stock Ĝřţ
CM350166-1g in stock ŁŁĜ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:1802924-13-5
Molekulare Formel:C12H15FN2O5
Schmelzpunkt:-
SMILES-Code:O=C(OC(C)(C)C)NC1=CC([N+]([O-])=O)=C(F)C=C1OC
Dichte:
Katalognummer:CM350166
Molekulargewicht:286.26
Siedepunkt:
Mdl-Nr.:
Lagerung:

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Osimertinib
TAGRISSO (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial.
TAGRISSO (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases. It is the first and only EGFR TKI recommended by NCCN Guidelines as an adjuvant treatment option for completely resected stage IB-IIIA, stage IIIB (T3, N2) EGFRm (exon 19 deletion, exon 21 L858R mutation) NSCLC.
Lazertinib
Johnson & Johnson announced new data from the Phase 2 PALOMA-2 study evaluating subcutaneous (SC) amivantamab combined with lazertinib as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations. These data showed a comparable response rate in patients treated with SC amivantamab and lazertinib compared to those treated with the intravenous (IV) formulation in the MARIPOSA study, which established the combination of amivantamab and lazertinib as superior to osimertinib. Lazertinib is an oral, third-generation, brain-penetrant EGFR tyrosine kinase inhibitor (TKI) that targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products